
Journal Pre-proof



Primary Operation with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-Year Follow-Up of Protocol MF07-01 Randomized Clinical Trial

Atilla Soran, MD, MPH, FNCBC, FACS, Vahit Ozmen, MD, FACS, Serdar Ozbas, MD, Hasan Karanlik, MD, FACS, Mahmut Muslumanoglu, MD, Abdullah Igci, MD, FACS, Nuh Zafer Canturk, MD, FACS, Zafer Utkan, MD, Turkkan Evrensel, MD, Efe Sezgin, PhD, for the MF07-01 Study Group

PII: S1072-7515(21)01963-3

DOI: https://doi.org/10.1016/j.jamcollsurg.2021.08.686

Reference: ACS 10476

To appear in: *Journal of the American College of Surgeons*

Received Date: 15 January 2021

Revised Date: 13 August 2021


Accepted Date: 17 August 2021

Please cite this article as: Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk NZ, Utkan Z, Evrensel T, Sezgin E, for the MF07-01 Study Group, Primary Operation with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-Year Follow-Up of Protocol MF07-01 Randomized Clinical Trial, *Journal of the American College of Surgeons* (2021), doi: https://doi.org/10.1016/j.jamcollsurg.2021.08.686.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American College of Surgeons.

Primary Operation with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-Year Follow-Up of Protocol MF07-01 Randomized Clinical Trial



Soran et al. J Am Coll Surg, December 2021

Journal Pre-proof

Journal Pre-proof

Primary Operation with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-Year Follow-Up of Protocol MF07-01 Randomized Clinical Trial

Atilla Soran, MD, MPH, FNCBC, FACS[1], Vahit Ozmen, MD, FACS[2], Serdar Ozbas, MD[3], Hasan Karanlik, MD, FACS[4], Mahmut Muslumanoglu, MD[2], Abdullah Igci, MD, FACS[2], Nuh Zafer Canturk, MD, FACS[5], Zafer Utkan, MD[5], Turkkan Evrensel, MD[6], Efe Sezgin, PhD[7], for the MF07-01 Study Group

1. Department of Surgery, University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, PA
2. Department of Surgery, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
3. Breast and Endocrine Surgeon, Ankara, Turkey
4. Surgical Oncology Unit, Istanbul University Institute of Oncology, Capa, Istanbul, Turkey
5. Department of Surgery, Kocaeli University School of Medicine, Kocaeli, Turkey
6. Department of Medical Oncology, Uludag University School of Medicine, Bursa, Turkey
7. Department of Food Engineering, Laboratory of Nutrigenomics and Epidemiology, Izmir Institute of Technology, Izmir, Turkey

Members of the MF07-01 Study Group who coauthored this article are listed in the Appendix.
Disclosure Information: Nothing to disclose.
Presented at the American College of Surgeons 105th Annual Clinical Congress, San Francisco, CA, October 2019.
ClinicalTrials.gov identifier number: NCT00557986

Correspondence:
Atilla Soran, MD, MPH, FNCBC, FACS
Clinical Professor of Surgery,
Department of Surgery, Division of Surgical Oncology,
University of Pittsburgh Medical Center, Magee-Womens Hospital
Fax: 412-641-1446; Phone: 412-641-1316
e-mail: asoran@upmc.edu, asoran65@gmail.com

Running Title: Primary Operation in Stage IV Breast Cancer

Introduction: The aim of this randomized clinical trial was to evaluate the overall survival (OS) data of patients diagnosed with *de novo* stage IV breast cancer (BC) who received locoregional treatment (LRT) over a 10-year follow-up.

Study Design: The MF07-01 is a 1:1 multicenter, randomized clinical trial to compare the LRT with systemic therapy (ST) where ST was given to all patients either immediately after randomization or after surgical resection of the intact primary tumor.

Results: A total of 278 patients were randomized and 265 patients were in the final analysis; at the 10-year follow-up, survival was 19% (95% CI 13-28) and 5% (95% CI 2-12) in the LRT group and ST group, respectively. Median survival was 46 months for the LRT and 35 months for the ST group and hazard of death was 29% lower in the LRT group compared to the ST group (HR= 0.71; 95% CI 0.59-0.86; p=0.0003).

Conclusion: Patients with the diagnosis of *de novo* stage IV BC who underwent LRT followed by ST had a 14% higher chance of OS by the end of the 10-year follow-up compared to the patients who received only ST. The longer study follow-up revealed that LRT should be presented to patients when discussing treatment options.

Keywords: *de novo*, metastasis, breast, cancer, surgery, survival

Journal Pre-proof

Introduction

Although the incidence of synchronous distant metastatic disease in newly diagnosed breast cancer (BC) patients has been relatively constant over the last decades (1-3), advances in

adjuvant therapies and a better understanding of tumor biology appear to have improved patient overall survival (OS) (4-6). Systemic therapy (ST) was considered the first and only choice for care in this patient population in most of the institutes until more data showed that locoregional treatment (LRT) provided better OS and locoregional control of the disease (7-19). In the last two decades, evidence of an OS benefit with primary surgery in *de novo* BC patients has been substantially increasing in the literature.

In 2002, Khan et al., using cases from the National Cancer Data Base (NCDB) of the American College of Surgeons, showed an OS benefit from local therapy in the stage IV setting (7). Retrospective studies and meta-analyses published between 2002-2013 suggest that primary tumor resection in appropriately selected *de novo* stage IV BC patients not only limits locoregional progression, but also prolongs disease-free survival and OS (7-19). These studies typically had selection biases and retrospective studies ended with suggesting the need for prospective studies. In 2015, Badwe et al. presented the first randomized clinical trial (RCT) to compare the effect of LRT vs. no treatment on outcomes in women with metastatic breast cancer at initial presentation suggesting that LRT is not associated with improved OS in *de novo* metastatic BC patients (20). Our group initiated the MF07-01 study in 2007 as a phase III, multicenter clinical RCT. The MF07-01 study comparing LRT with primary ST in *de novo* stage IV BC patients found a statistically significant improvement in OS with primary surgery at the median 40-month (Range: 1,131) follow-up (21). Recently, Khan et al. presented the results of the multicenter, phase 3, ECOG-ACRIN 2108 study at the plenary session of the American Society of Clinical Oncology (ASCO) 2020 virtual meeting. They found no statistical difference in terms of three-year OS (68.4% vs. 67.9%) (hazard ratio (HR) = 1.09; 90% confidence interval (CI) 0.80-1.49; p=0.63). In addition, no progression-free survival benefit was observed between the ST and early LRT groups (p=0.40) (22).

The objective of current study was to evaluate the importance of LRT in patients diagnosed with *de novo* stage IV BC on the OS over a 10-year follow-up.

Methods

Between November 2007 - December 2012, 312 patients were recruited for the MF07-01 trial. Thirty-four patients did not meet inclusion criteria, 13 withdrew from the study during follow-up, and 265 patients were evaluated in the final analysis (LRT group, n=134; ST group, n=131) (Figure 1). Patient and tumor characteristics, treatment, and metastatic site distribution are presented in Table 1.

The MF07-01 trial study protocol was published in 2009 (23). Participating centers obtained local ethics committee approval before entering the study. Randomization of subjects was done centrally by data center computer through internet. Study design and accrual methods along with survival data for patients with a median 40-month (Range: 1,131) follow-up were also presented in detail in our previous publication (21). However, we want to express once again that the MF07-01 trial design is different than most of the published or presented prospective series. In this trial, eligible patients were randomly assigned to one of two study arms: (a) LRT with subsequent ST, or (b) primary ST. Patients in the LRT group received ST after primary tumor resection, whereas ST group patients began receiving ST immediately after randomization.

Some of the pitfalls of the MF07-01 randomized study is that LRT group patients had higher rates of estrogen receptor (ER)/progesterone receptor (PR) positivity (86% vs. 73%, p=0.01) and lower rates of triple negative (TN) tumors (7% vs. 18%, p=0.01) compared to patients in the ST group.

Statistical Analysis:

Kaplan-Meier survival curves were used, and the survival curves for treatment arms were compared using log-rank tests. Univariate and multivariable Cox models adjusted for clinical,

tumor, and metastasis characteristics were used to estimate HR and 95% CI for survival. For all Cox models the proportional hazards assumption was tested using the scaled Schoenfeld residuals (P values > 0.20). P-values less than 0.05 were considered statistically significant. Statistical analyses were conducted with R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria, https://www.r-project.org) software packages.

Results

At the 10-year follow-up hazard of death was 29% lower in the LRT group compared to the ST group (HR= 0.71; 95% CI 0.59-0.86; p=0.0003) (Figure 2). It is important to note that OS was similar for the LRT and ST groups (60%, 95% CI 51-68 and 51%, 95% CI: 42-59, respectively, p=0.10) at three-years follow-up. However, by the five-year follow-up, 42% of patients had survived in the LRT group and only 24% (95% CI 32.5-50.4 and 95% CI 17-33, respectively, p=0.005) had survived in the ST group (21). By the end of the 10-year follow-up, 19% of patients had survived in the LRT group and 5% had survived in the ST group (p=0.0003).

Figure 3 shows a forest plot analysis of OS subgroup analyses with HRs. At 10-year follow-up, OS was statistically higher in the LRT group than in the ST group with respect to ER/PR (+) (HR= 0.71; 95% CI 0.58-0.88; p=0.002) (eFigure 1), HER2/neu (-) (HR= 0.72; 95% CI 0.58-0.90; p=0.004) (eFigure 2), patients < 55 years old (HR= 0.67; 95% CI 0.53-0.87; p=0.002) (eFigure 3), and patients with solitary bone only metastases (HR= 0.55; 95% CI 0.36-0.86; p=0.009) (eFigure 4). These data are very similar with respect to our previous publication of five-year follow-up analysis. However, at the 10-year follow-up, we found that OS was also statistically significant higher in the LRT group than in the ST group in HER2/neu (+) patients (HR= 0.69; 95% CI 0.85-0.98; p=0.04) (eFigure 5), and slightly better in patients ≥ 55 years old (HR= 0.75; 95% CI 0.57-0.99; p=0.045) (eFigure 6).

In patients with TN subtype, at 10-year follow-up, nine of 10 (90%) patients had died, with a median survival of 17.5 months in the LRT group, and 21 of 23 (91%) patients died, with a

median survival of 18 months in the ST group (HR= 0.88; 95% CI 0.51-1.54; p=0.66) (eFigure 7). A similar OS was found for ER/PR (-) patients at 10-year follow-up. Median survival was 17 and 19 months for the LRT and ST groups, respectively (HR=1.03; 95% CI 0.69-1.55; p=0.88). Only one patient was alive in each group (eFigure 8).

Median survival was 6.5 months longer in the LRT group compared with the ST group in bone only metastasis patients, but this difference was not significant (HR= 0.8; 95% CI 0.61-1.04; p=0.1) (eFigure 9). In the solitary bone metastasis subgroup, median survival was 14 months longer in the LRT group compared with the ST group (HR= 0.55; 95% CI 0.36-0.86; p=0.009) (Figure 3). However, the difference was only three months in the multiple bone metastasis group and was not significant (p=0.59) (Figure 3).

At the 10-year follow-up, solitary pulmonary/liver metastases and multiple pulmonary/liver metastases patients had no survival benefit from LRT (HR= 0.69; 95% CI 0.37-1.29 and HR= 1.14; 95% CI 0.63-2.08, respectively) (Figure 3).

Locoregional progression (LRP) was found higher in the ST group: it was 1% (n=2) in the LRT group and 14% (n=18) in the ST group (p=0.001) at 10 years. Nine patients (50%) received loco-regional radiation therapy and 3 (17%) patients underwent loco-regional surgery in the ST group after LRP.

In a multivariable Cox proportional model with significant baseline and clinical characteristics, survival was independently associated with LRT (HR= 0.79; 95% CI 0.65-0.96; p=0.02), ER/PR (+) (HR= 0.61; 95% CI 0.46-0.82; p=0.001), bisphosphonate use (HR= 0.61; 95% CI 0.42-0.89; p=0.01), and more than two organ metastases at initial presentation (HR= 1.54; 95% CI 1.15-2.05; p=0.003) (Table 2).

Discussion

Although conclusions about OS benefits with surgery in *de novo* metastatic BC in the literature have been conflicting, National Comprehensive Cancer Network guidelines and metanalysis

recommends LRT in selected patients (24). Recently published the largest meta-analysis and NCDB results showed that LRT resulted in a 31.8% to 36.2% reduction in mortality, and especially surgery followed by RT had the highest three-year OS of 69.4%, in addition to ST (25,26). The MF07-01 trial is the first randomized study to show a statistically significant improvement in median OS with primary surgery; this benefit was found to be more significant as the follow-up period increases. In the first analysis after the three-year follow-up, OS was similar for the LRT and ST groups. In 2018, we published the five-year follow-up MF07-01 study data and showed that 41.6% and 24.4% of patients were alive in the LRT and ST groups, respectively (p=0.005). In the current analysis, OS was 19% (95% CI 13-28) and 5% (95% CI 2-12) in the LRT group and ST group, respectively at 10-year follow-up. A similar 10-year survival benefit was seen in a study that reviewed 24,015 cases from the NCDB, where five- and 10-year OS were 41.1% and 14.4%, respectively, in the surgery before ST group, compared to 27.5% and 8.5%, respectively, in the ST alone group (p<0.001) (27).

In one of the earlier RCTs, an Indian study, LRT did not show an OS benefit compared to no LRT. However, 26% of LRT patients and 35% of no-LRT patients had tumors positive for Her2/neu; none of those patients received targeted therapy in the LRT group, and 15% received such therapy in the no-LRT group (20). Khan et al. presented the results of the multicenter, phase 3, ECOG-ACRIN 2108 study at the plenary session of the ASCO 2020 virtual meeting. They assigned 256 eligible patients to ST based on patient and tumor characteristics. Those who did not progress during four to eight months of treatment were then assigned to continue ST alone (n=131) or ST plus LRT +/- radiation (n=125). They found no statistical difference between two groups in terms of three-year OS (68.4% vs. 67.9%) (HR= 1.09, 90% CI 0.80-1.49; p=0.63). In addition, no progression-free survival benefit was observed between the ST and early LRT groups (p=0.40). However, LRP or progression was significantly higher in the ST arm alone (25.6% vs. 10.2%; p=0.003). They concluded that based on the available data,

patients with *de novo* metastatic BC should not be offered LRT for primary tumor with the expectation of OS benefit (22). This study presentation is criticized for its failure to obtain negative surgical margins in 20% of patients in the LRT group. Another criticism of this study is its significant portion of patients with high tumor burden; 44% of patients had fascia and skin invasion with nodules and 48% had T4 and/or N2/3 disease. We will get answers to questions about this RCT when the manuscript is published (28).

Regarding our analysis and previous studies, ER status, young age, and tumor burden are important risk factors in determining good candidates for initial surgery. At five-year and 10-year follow-up, we found a significant OS benefit with primary surgery in patients with ER/PR (+), HER2/neu (-), patients with solitary bone metastasis, and younger patients < 55 years old. Co M, et al. evaluated *de novo* metastatic BC patients between 2007 and 2016 from a prospectively maintained database. They found that five-year OS in the surgical group was significantly better than that in the non-surgical group (43.9% vs. 33.9%; p=0.026). Multivariable analysis found that positive ER status was the only positive prognostic factor in the analysis (HR= 0.42, 95% CI 0.25–0.68; p=0.001) (29).

One of the important findings from 10-year follow-up data that differs from our previous publication was the benefit of LRT in HER2/neu (+) patients. A median eight-month OS benefit was found between the LRT and ST groups (HR= 0.69, 95% CI: 0.85-0.98; p=0.04). Mudgway R et al. evaluated the impact of primary tumor resection on OS in HER2/neu (+) stage IV BC patients by using NCDB. They found that surgery was associated with improved OS (HR= 0.56, 95% CI: 0.40-0.77), and in the subgroup analysis of LRT of the primary site for metastatic HER2/neu (+) BC, it was found to be associated with improved OS in selected patients (30).

In the MF07-01 study, most patients with TN subtype and ER/PR (-) died during follow-up. Median OS for TN patients was 17.5 and 18 months for the LRT and ST groups, respectively (HR= 0.88, 95% CI 0.51-1.54; p=0.66). In ER/PR (-) patients, the median OS was 17 and 19

months in the LRT and ST groups, respectively (HR=1.03, %95 CI 0.69-1.55; p=0.88). OS was similar in these TN and ER/PR (-) patients. Pons-Tostivint et al. conducted a multicenter retrospective study of 4,276 women diagnosed with *de novo* metastatic BC selected from the French Epidemiological Strategy and Medical Economics database between 2008 and 2014. LRT was associated with a significantly better OS in *de novo* metastatic BC patients, including patients with visceral involvement at diagnosis. However, LRT did not impact OS in TN patients (31). In a previous retrospective study, Neuman et al. stated that the OS benefit with primary breast surgery in stage IV BC was limited to patients with ER/PR (+) or HER-2/neu (+) tumors, but patients with TN disease did not experience any differential improvement in OS (32).

The OS benefit offered by surgery for *de novo* stage IV BC varies by metastatic tumor burden. The incidence of solitary bone metastases was similar between cohorts (23% in the LRT group and 15% in the ST group, $p > 0.05$) in the MF07-01 study. Solitary bone metastasis patients' median OS was 14 months longer in the LRT group compared to the ST group (HR= 0.55, 95% CI 0.36-0.86; p=0.009). Hazard of death was 45% less in the solitary bone metastasis group in the LRT group compared with the ST group. Based on retrospective studies and the prospectively-maintained database by Co M, et al., the presence of visceral metastasis (HR= 1.67, 95% CI 1.03–2.72; p=0.038) was a significant adverse prognostic factor through multivariable analysis (11,28,33). This finding was similar in the MF07-01 trial showing that upfront LRT had a significantly worse prognosis in patients with liver/pulmonary metastases. Although a limited number of patients were included in this analysis, only 20% of patients (n=11) had survived at the 10-year follow-up in pulmonary/liver metastasis. However, in solitary pulmonary/liver metastatic patients, the scenario may be different. Ten-year follow-up data from the MF07-01 trial showed that 38% of patients (n=5) in the LRT group and 7% (n=1) in the ST group had survived at 10-year follow-up. Two patients in the LRT group had liver

metastasis interventions. The prognosis of patients with solitary solid organ metastasis may differ from the that of patients with multiple metastases. Wang K et al. conducted a retrospective cohort study with *de novo* stage IV BC patients diagnosed between 2010-2015 based on the SEER database, aiming to determine the OS benefit of primary surgery on the basis of metastatic pattern. The weighted three-year OS for the surgery group was 54.5%, compared to 47.7% ($p<0.001$) for the non-surgery group. The magnitude of difference in OS with surgery was significantly correlated with metastatic patterns ($p<0.05$). Significant survival improvements in the surgery group compared with the non-surgery group were observed in patients with bone-only metastasis (adjusted HR= 0.83, $p<0.05$) or multiple metastases with bone involved (adjusted HR= 0.76, $p<0.05$), whereas an OS inferiority of surgery was found for patients with multiple visceral organ-only metastases (adjusted HR= 2.08, $p<0.05$) (34). By the end of the 10-year analysis of the MF07-01 study, the percentage of surviving patients in all bone (solitary bone, multiple bone, bone with visceral organ metastasis) group was 44% (n=15); in the no bone metastasis group (visceral organ only metastasis), it was 15% for the LRT group, whereas in the ST group, the percentages of surviving patients were 32% (n=11) and 9% (n=3) for all bone and no bone metastasis groups, respectively.

Meta-analyses showed that the OS advantage of LRT is more pronounced in patients with less metastatic burden and metastasis in only one site, especially those with bone only metastasis (18,19). In our analysis at the 10-year follow-up, the multivariable Cox proportional model showed that the hazard of death was higher in patients with more than two organ metastases at initial presentation (HR=1.54, p=0.003). Multivariable logistic regression models also indicated that two or more organ metastases (OR=0.44, p=0.01) were associated with adverse prognostic factors with OS beyond five years.

At the ten-year follow-up, we found that the rate of LRP was 14 times higher in the ST group (14% in the ST vs 1% in the LRT group) and concluded that LRT controls LRP in *de novo* stage IV BC patients in whom long OS is expected.

The results of the studies showing an OS benefit from LRT in patients with *de novo* metastatic BC presents the question of whether the advantage of surgery causes a worse quality of life (QoL) in those patients. One of the secondary endpoints of the MF07-01 study was QoL measurements. The MF07-01Q study aimed to evaluate QoL in patients who had LRT in order to learn whether prolonged OS after LRT is accompanied by a decline in QoL. The MF07-01Q study demonstrated that LRT has no detrimental effect on QoL compared to ST only in patients who lived longer than three years. However, we found that the toxic effects of continued ST may cause lower physical QoL scores when compared to those of the general population and stage I-III BC patients (35). Khan et al. also presented HRQoL measurements from their study at ASCO 2020. Although there was no significant difference in HRQoL measurements between both groups at six and 30 months, it was worse in the early LRT arm at the 18-month evaluation (22). Si Y et al. evaluated the effect of local resection on controlling local symptoms and improving QoL in *de novo* stage IV BC patients. They defined a new term called "local progress/recurrence of symptoms" (LPRS) to refer to the local problems caused by tumor progression/recurrence. They found that primary surgery could reduce the occurrence of LPRS and patients without LPRS had longer OS (45 months vs. 2.9 months, p=0.001). QoL in patients with *de novo* stage IV BC can be improved by reducing the incidence of local symptoms through primary tumor surgery (36).

Conclusion

Patients' OS in the setting of *de novo* metastatic BC is better today than it was a decade ago, and 10-year follow-up of the MF07-01 study suggests that primary surgery plays a role, especially in some of the patient groups. While waiting for the JCOG 1017 trial results, results

from studies with methodologies similar to those of the MF07-01 study should be considered for future treatment of *de novo* stage IV BC patients, and the possibility of LRT to prolong the OS and for loco-regional control should be discussed by the tumor board.

Younger age, tumor molecular type, less metastatic disease burden (especially bone only and solitary bone), and performance status and comorbidities are important factors in favor of surgery in such patients.

Acknowledgments: Thanks to Christine Burr, Scientific Writer, from the University of Pittsburgh, for her assistance with language editing, and as well as Umit Ugurlu, MD, from Marmara University, Betul Bozkurt, MD, from Hitit University, Ali Uzunkoy, MD, from Harran University, Neset Koksal, MD, from Yeditepe University, Bulent Unal, MD, from Osmangazi University, Can Atalay, MD, from VKV Amerikan Hospital Istanbul, Semra Salimoglu, MD, from Izmir SBU Tepecik Teaching and Research Hospital, Atakan Sezer, MD, from Trakya University, Ayhan Koyuncu, MD, from Medicana Sivas Hospital, Gunay Gurleyik, MD, from Haydarpasa Numune Teaching and Research Hospital, Nalan Ulufi, MD, from Medical Park Pendik Hospital, Omer Cengiz, MD, from Koru Ankara Hospital, Mustafa Dulger, MD, from Kocaeli Cihan Hospital, and Ugur Berberoglu, MD, Emin Yildirim, MD, Haluk Alagol, MD, and Temel Dagoglu, MD for patient recruitment.

We also thank Ronald Johnson, MD, FACS, Department of Surgery, UPMC Magee-Womens Hospital, Pittsburgh, PA, for his guidance and contributions during the data analysis.

Appendix

Members of the MF07-01 Study Group: Cihangir Ozaslan, MD, Department of Surgery, Ankara Oncology Teaching and Research Hospital, Ankara, Turkey, Cihan Uras, MD, Department of Surgery, Acibadem University School of Medicine, Istanbul, Turkey, MD, Erol Aksaz, MD,

Mamer Medical Center, Bursa, Turkey, Aykut Soyder, MD., Department of Surgery, Acibadem Altunizade Hospital, Istanbul, Turkey, Cavit Col, MD, Department of Surgery, Middle East Hospital, Ankara, Turkey, Neslihan Cabioglu, MD, Department of Surgery, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, Bahadir M Gulluoglu, MD, FACS, Department of Surgery, Marmara University School of Medicine, Istanbul, Turkey, Ergun Erdem, MD, Department of Surgery, Pamukkale University School of Medicine, Denizli, Turkey.

Journal Pre-proof

REFERENCES

1. Carmichael AR, Anderson EDC, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2003;29:17-19.
2. Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 2007;14:2187-2194.
3. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Does surgical management of stage IV breast cancer affect outcome? Ann Surg 2008;247:732-738.
4. Hortobagyi GN. Treatment of breast cancer. N Eng J Med 1998;339:974-984.
5. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004;100:44-52.
6. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-3308.
7. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620-627.
8. Khan SA. Primary tumor resection in stage IV breast cancer: consistent benefit, or consistent bias? Ann Surg Oncol 2007;14: 3285-3287.
9. Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776-782.
10. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-2749.

Journal Pre-proof

11. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007;14:3345-3351.
12. Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995;13:2869-2878.
13. Hazard HW, Gorla SR, Scholtens D, et al. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 2008;113:2011-2019.
14. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-718.
15. Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2009;115:117-112.
16. Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009;35:1146-1151.
17. Shien T, Kionoshita T, Shimzu C, et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep 2009;21:827-832.
18. Harris E, Barry M, Kell MR. Meta-Analysis to Determine if Surgical Resection of the Primary Tumour in the Setting of Stage IV Breast Cancer Impacts on Survival. Ann Surg Oncol 2013; 20:2828-2834.
19. Petrelli F, Barni S. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 2012;29:3282-3290.

Journal Pre-proof

20. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 2015;16:1380-1388.
21. Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol 2018;25:3141-3149.
22. Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol 2020; 38(Suppl): pp.LBA2.
23. Soran A, Ozbas S, Kelsey SF, Gulluoglu BM. Randomized trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (Protocol MF07-01): a study of Turkish Federation of the National Societies for Breast Disease. Breast J 2009;15:399-403.
24. NCCN guidelines version 6.2020 Breast Cancer.
Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
25. Gera R, Chehade HELH, Wazir U, et al. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis. Sci Rep 2020;10: 2952.
26. Kim KN, Qureshi MM, Huang D, et al. The impact of locoregional treatment on survival in patients with metastatic breast cancer: A National Cancer Database analysis. Clin Breast Cancer 2020;20:200-213.
27. Lane WO, Thomas SM, Blitzblau RC, et al. Surgical resection of the primary tumor in women with de novo stage IV breast cancer: Contemporary practice patterns and survival analysis. Ann Surg 2019;269:537-544.

Journal Pre-proof

28. Soran A, Ozbas S, Dogan L, et al. Loco-regional treatment for intact primary tumor in patient with de novo metastatic breast cancer; comments and concerns of ECOG-ACRIN 2108 trial (Editorial). Eur J Breast Health 2020;16:158-159.
29. Co M, Ng J, Kwang A. De-novo metastatic breast cancers with or without primary tumor resection – A 10-year study. Cancer Treat Res Commun 2019;19:100-118.
30. Mudgway R, Villaneuva CCP, Lin AC, et al. The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy. Ann Surg Oncol 2020;27:2711-2720.
31. Pons-Tostivint E, Kirova Y, Lusque A, et al. Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: A propensity score-matched analysis. Ann Surg Oncol 2019;26:356-365.
32. Neuman HB, Morrogh M, Gonen M, et al. Stage IV Breast Cancer in the Era of Targeted Therapy. Does Surgery of the Primary Tumor Matter? Cancer 2010;116:1226-1233.
33. Nguyen DH, Truong PT, Walter CV, et al. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol 2012;19:3028-3034.
34. Wang K, Shi Y, Li ZY, et al. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study. Eur J Surg Oncol 2019;45:1364-1372.
35. Soran A, Soyder A, Ozbas S, et al. The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q. Support Care Cancer 2021;29:3823-3830.
36. Si Y, Yuan P, Hu N, et al. Primary tumor surgery for patients with de novo Stage IV breast cancer can decrease local symptoms and improve quality of life. Ann Surg Oncol 2020;27:1025-1033.

Journal Pre-proof

Table 1. Demographic, Clinical, Treatment, and Tumor Characteristics Comparisons Between the Locoregional Treatment and Systemic Therapy Groups

Characteristic	**LRT (n = 134)**	**ST (n = 131)**	**p Value**
Age, y mean ± SD	51.9 ± 12.7	51.7 ± 13.5	0.93
BMI, kg/m^2, mean ± SD	27.4 ± 5.1	27.9 ± 5.1	0.43
Follow-up, mo, mean ± SD	55.6 ± 38.9	41.1 ± 31.1	0.001
Follow-up, median (IQR)	46 (23,56)	35 (18,41)	0.01
Tumor size, cm, n (%)			0.24
T1	12 (9)	11 (8)	
T2	68 (51)	55 (42)	
T3	30 (22)	28 (21)	
T4	24 (18)	37 (28)	
Histologic grade*, n (%)			0.18
Grade I	6 (4)	9 (9)	
Grade II	54 (40)	31 (31)	
Grade III	74 (55)	60 (60)	
Tumor type, n (%)			0.38
Invasive ductal	105 (78)	110 (85)	
Invasive lobular Mixed tumor type Others	15 (11) 10 (7) 4 (4)	11 (8) 5 (4) 5 (3)	
ER/PR(+)†, n (%)	115 (86)	95 (73)	0.01
Her 2/neu(+)†, n (%)	40 (30)	37 (28)	0.80
Triple negative, n (%)	10 (7)	23 (18)	0.01
Treatment, n (%)			
BCS + axillary evaluation	35 (26)	-	NA
M + axillary evaluation	99 (74)	-	NA
SLNB‡	21 (16)	-	NA
ALND	134 (100)	-	NA
Positive LN	120 (90)	-	NA
Intervention to metastasis	34 (25)	42 (32)	0.23
Anthracycline-based CT	124 (93)	115 (88)	0.26
Bisphosphonates	28 (28)	18 (20)	0.20
Metastasis site, n (%)			
All bone	100 (75)	88 (67)	0.18
No bone	34 (25)	43 (33)	
Solitary/multiple metastasis, n (%)			0.82
Solitary bone	31 (23)	20 (15)	
Multiple bone	37 (28)	34 (26)	
Solitary pulmonary or liver	13 (10)	15 (11)	
Multiple pulmonary or liver	13 (10)	14 (11)	

Distribution of categorical values between the two groups is tested with chi-square tests.
*Missing data; 31 patients in the ST group.

†Patients with ER/PR (+) tumor received hormonal therapy, and patient with Her2/neu (+) received trastuzumab.
‡SLNB (+) patients underwent ALND.
ALND, axillary lymph node dissection; BCS, breast-conserving surgery; CT, chemotherapy; ER, estrogen receptor; Her2, Her2/neu; IQR, interquartile range; LN, lymph node; LRT, locoregional treatment; M, mastectomy; NA, not applicable; PR, progesterone receptor; SLNB, sentinel lymph node biopsy; ST, systemic therapy

Journal Pre-proof

Table 2. Univariate and Multivariable Cox Model Analysis of Overall Survival for Clinically İmportant Parameters

Parameter	**HR**	**95% CI**	**p Value**	**HR*$_{adj}$**	**95% CI**	**p Value**
LRT	0.71	0.59-0.86	0.0003	0.79	0.65-0.96	0.02
Age < 55	0.78	0.60-1.02	0.07	0.97	0.71-1.33	0.87
T2 tumor	1.43	1.00-2.05	0.05	1.23	0.85-1.79	0.26
ER/PR (+)	0.57	0.46-0.71	<0.0001	0.61	0.46-0.82	0.001
Triple-negative	1.53	1.16-2.00	0.002	0.98	0.69-1.40	0.93
Bisphosphonate usage†	0.59	0.41-0.86	0.005	0.61	0.42-0.89	0.01
≥2 organ metastases	1.48	1.12-1.97	0.006	1.54	1.15-2.05	0.003

* Adjusted HR results from multivariable Cox models constructed with only significant univariate model variables.

†Considering patients with bone-only metastasis

ER, estrogen receptor; HR, hazard ratio; LRT, loco regional treatment; PR, progesterone receptor

Journal Pre-proof

Figure Legends

Figure 1: Consolidated Standards of Reporting Trials flow diagram.

Figure 2: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups. HR, hazard ratio.

Figure 3: Forest plot of overall survival subgroup analyses with un-adjusted hazard ratio estimates. ER, estrogen receptor; Met, metastasis; PR, progesterone receptor.

eFigure 1: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are estrogen receptor/ progesterone receptor positive. HR, hazard ratio.

eFigure 2: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are HER2 negative. HR, hazard ratio.

eFigure 3: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are younger than age 55. HR, hazard ratio.

eFigure 4: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups stratified by solitary bone metastasis status. HR, hazard ratio.

eFigure 5: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are HER2 positive. HR, hazard ratio.

eFigure 6: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are of age 55 and older. HR, hazard ratio.

eFigure 7: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are triple negative. HR, hazard ratio.

eFigure 8: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who are ER/PR negative. HR, hazard ratio.

eFigure 9: Comparison of overall survival between the locoregional treatment (LRT) and systemic therapy (ST) groups among patients who have bone only metastasis. HR, hazard ratio.

Precis

The final analysis of the MF07-01 randomized study shows improvement in median overall survival during the 10-year follow-up period for patients who underwent primary breast operation for de novo stage IV breast cancer.

Journal Pre-proof

AUTHOR CONTRIBUTIONS FORM

Individuals claiming authorship should **meet all 3 of the following conditions** in accordance with the "Consensus Statement on Surgery Journals Authorship—2005":

1) Authors make substantial contributions to conception and design, and/or acquisition of data, and/or analysis and interpretation of data;

2) Authors participate in drafting the article or revising it critically for important intellectual content; and

3) Authors give final approval of the version to be submitted and any revised version.

Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. **Allowing one's name to appear as an author without having contributed significantly to the study or adding the name of an individual who has not contributed or who has not agreed to the work in its current form is considered a breech of appropriate authorship.**

Ghost-writing is NOT acceptable. No one, other than the authors listed below, should have contributed substantially to the writing and revising of the manuscript. Contributors who do not meet the criteria for authorship should be listed in the acknowledgment. Examples include: individuals who allowed their clinical experience to be included, a person who provided purely technical help, copyediting, proofreading or translation assistance (NO ghostwriters allowed), or a department Chair who provided only general support.

Groups of persons who have contributed materially to the paper, but whose contributions do not justify authorship may be listed under a heading such as "clinical investigators" or "participating investigators," and their function or contribution should be described; for example, "served as scientific advisors," "critically reviewed the study proposal."] If you have any question about this, contact that editorial office before submitting your manuscript at jacsedit@facs.org or 312-202-5316.

* * *

Please type each author's **LAST NAME** next to the appropriate category.

Study conception and design: SORAN, OZMEN, OZBAS

Acquisition of data: OZMEN, OZBAS, KARANLIK, MUSLUMANOGLU, IGCI, CANTURK, UTKAN, OZASLAN, EVRENSEL, URAS, AKSAZ SOYDER, COL, CABIOGLU, GULLUOGLU, ERDEM

Analysis and interpretation of data: SORAN, OZBAS, SEZGIN


Drafting of manuscript: SORAN, OZBAS, SEZGIN

Critical revision: SORAN, OZMEN, OZBAS, SEZGIN


Journal Pre-proof

Journal Pre-proof

Journal Pre-proof



Journal Pre-proof




	N	Death	Median (months)	HR (95%CI)	P
LRT	134	108	46	0.71 (0.59-0.86)	0.0003
ST	131	123	35		

Number at Risk/Cumulative Dead

LRT	134/0	81/53	54/80	10/106
ST	131/0	65/66	30/101	4/122

Journal Pre-proof

Subgroup	LRT Event	LRT Total	ST Event	ST Total	Hazard Ratio (95% CI)
ER_PR Positive	90	115	88	95	0.71 (0.58-0.88)
ER_PR Negative	18	19	34	35	1.03 (0.69, 1.55)
HER2 Positive	31	40	34	37	0.69 (0.48, 0.98)
HER2 Negative	77	94	88	93	0.72 (0.58, 0.90)
Triple Negative	9	10	21	23	0.88 (0.51, 1.54)
Age<55	61	76	70	76	0.67 (0.53, 0.87)
Age≥55	47	58	53	55	0.75 (0.57, 0.99)
Bone only Met	59	68	50	54	0.80 (0.61, 1.04)
Other Mets noBone	23	34	40	43	0.74 (0.51, 1.07)
Solitary Bone Met	28	31	19	19	0.55 (0.36, 0.86)
Multiple Bone Met	31	37	31	35	0.91 (0.64, 1.29)
Solitary Pulmonary/Liver Met	8	13	14	15	0.69 (0.37, 1.29)
Multiple Pulmonary/Liver Met	10	13	12	14	1.14 (0.63, 2.08)



Journal Pre-proof